Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: